Müller Dominik, Kausalya P Jaya, Bockenhauer Detlef, Thumfart Julia, Meij Iwan C, Dillon Michael J, van't Hoff William, Hunziker Walter
Department of Pediatric Nephrology, Charite Children's Hospital and Center for Cardiovascular Research, 12200 Berlin, Germany.
J Clin Endocrinol Metab. 2006 Aug;91(8):3076-9. doi: 10.1210/jc.2006-0200. Epub 2006 May 16.
Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) is caused by a dysfunction of Claudin-16 (CLDN16) and characterized by renal wasting of Mg(2+) and Ca(2+).
The objectives of this study were to study the clinical parameters in suspected FHHNC patients, identify mutations in the CLDN16 gene, and analyze molecular defects associated with the mutant protein.
DESIGN, SETTING, AND PARTICIPANTS: CLDN16 genes from two siblings diagnosed with FHHNC were sequenced. Expression and characterization of the mutant protein in renal MDCK cells were studied.
Standard urine and serum parameters to diagnose FHHNC were determined. Mutations in the CLDN16 gene were identified. The subcellular distribution of the mutant protein was analyzed by immunofluorescence microscopy.
Urine and blood analysis showed signs typical for FHHNC. One patient, in addition, presented with hypocalcemic tetany, a phenomenon so far not described for FHHNC. Both siblings carry a novel mutation in CLDN16, Y207X. The review of medical records showed that hypocalcemia is not uncommon in the early childhood of FHHNC patients. Expressed in MDCK cells, the Y207X mutant is not detected at tight junctions but instead is found in lysosomes and, to a lesser extent, the endoplasmic reticulum. Surface expression can be rescued by inhibiting clathrin-mediated internalization.
We propose that mutations in CLDN16 are considered in childhood hypocalcemia. CLDN16 Y207X is transiently delivered to the plasma membrane but not retained and is rapidly retrieved by internalization. Inhibitors of endocytosis may provide novel therapeutic strategies.
家族性低镁血症伴高钙尿症和肾钙质沉着症(FHHNC)由Claudin-16(CLDN16)功能障碍引起,其特征为肾脏对镁离子(Mg²⁺)和钙离子(Ca²⁺)的浪费。
本研究的目的是研究疑似FHHNC患者的临床参数,鉴定CLDN16基因中的突变,并分析与突变蛋白相关的分子缺陷。
设计、地点和参与者:对两名被诊断为FHHNC的兄弟姐妹的CLDN16基因进行测序。研究了突变蛋白在肾MDCK细胞中的表达和特性。
确定诊断FHHNC的标准尿液和血清参数。鉴定CLDN16基因中的突变。通过免疫荧光显微镜分析突变蛋白的亚细胞分布。
尿液和血液分析显示出FHHNC的典型体征。此外,一名患者出现了低钙性手足搐搦,这是迄今为止FHHNC中尚未描述的现象。两名兄弟姐妹均在CLDN16中携带一种新突变,即Y207X。病历回顾显示,低钙血症在FHHNC患者的幼儿期并不罕见。在MDCK细胞中表达时,Y207X突变体在紧密连接处未被检测到,而是在溶酶体中被发现,在内质网中发现的程度较小。通过抑制网格蛋白介导的内吞作用可以挽救表面表达。
我们建议在儿童低钙血症中考虑CLDN16突变。CLDN16 Y207X短暂地转运到质膜,但未被保留,并通过内吞作用迅速被回收。内吞作用抑制剂可能提供新的治疗策略。